Selected article for: "low expression and lung inflammatory response"
Author: Wang, Wei; Li, Sha-sha; Xu, Xin-feng; Yang, Chan; Niu, Xiao-ge; Yin, Shu-xian; Pan, Xiao-yan; Xu, Wei; Hu, Guo-dong; Wang, Chan; Liu, Shu-wen
Title: Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation
  • Cord-id: 8nj2e1jk
  • Document date: 2021_7_15
    • ID: 8nj2e1jk
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce acute inflammatory response like acute lung inflammation (ALI) or acute respiratory distress syndrome, leading to severe progression and mortality. Therapeutics for treatment of SARS-CoV-2-triggered respiratory inflammation are urgent to be discovered. Our previous study shows that Salvianolic acid C potently inhibits SARS-CoV-2 infection. In this study, we investigated the antiviral effects of a Salvia miltiorrhiza compound
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce acute inflammatory response like acute lung inflammation (ALI) or acute respiratory distress syndrome, leading to severe progression and mortality. Therapeutics for treatment of SARS-CoV-2-triggered respiratory inflammation are urgent to be discovered. Our previous study shows that Salvianolic acid C potently inhibits SARS-CoV-2 infection. In this study, we investigated the antiviral effects of a Salvia miltiorrhiza compound, Danshensu, in vitro and in vivo, including the mechanism of S protein-mediated virus attachment and entry into target cells. In authentic and pseudo-typed virus assays in vitro, Danshensu displayed a potent antiviral activity against SARS-CoV-2 with EC(50) of 0.97 μM, and potently inhibited the entry of SARS-CoV-2 S protein-pseudo-typed virus (SARS-CoV-2 S) into ACE2-overexpressed HEK-293T cells (IC(50) = 0.31 μM) and Vero-E6 cell (IC(50) = 4.97 μM). Mice received SARS-CoV-2 S via trachea to induce ALI, while the VSV-G treated mice served as controls. The mice were administered Danshensu (25, 50, 100 mg/kg, i.v., once) or Danshensu (25, 50, 100 mg·kg(-1)·d(-1), oral administration, for 7 days) before SARS-CoV-2 S infection. We showed that SARS-CoV-2 S infection induced severe inflammatory cell infiltration, severely damaged lung tissue structure, highly expressed levels of inflammatory cytokines, and activated TLR4 and hyperphosphorylation of the NF-κB p65; the high expression of angiotensinogen (AGT) and low expression of ACE2 at the mRNA level in the lung tissue were also observed. Both oral and intravenous pretreatment with Danshensu dose-dependently alleviated the pathological alterations in mice infected with SARS-CoV-2 S. This study not only establishes a mouse model of pseudo-typed SARS-CoV-2 (SARS-CoV-2 S) induced ALI, but also demonstrates that Danshensu is a potential treatment for COVID-19 patients to inhibit the lung inflammatory response.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and acute phase protein: 1
    • absence presence and acute pneumonia: 1, 2, 3, 4, 5, 6, 7
    • absence presence and acute pneumonia ards respiratory distress syndrome: 1
    • absence presence and acute sars cov respiratory syndrome cov: 1, 2, 3
    • absence presence and administration route: 1
    • absence presence and lung damage: 1, 2
    • absence presence and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absence presence and lung inflammation model: 1
    • absence presence and lung inflammatory factor: 1
    • absence presence and lung injury: 1, 2, 3, 4
    • absence presence and lung serum: 1
    • absence presence and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and macrophage infiltration: 1
    • activate inflammatory cytokine and lung damage: 1
    • activate inflammatory cytokine and lung inflammation: 1
    • activate inflammatory cytokine and lung injury: 1
    • acute lung inflammation and lung damage: 1, 2, 3, 4
    • acute lung inflammation and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74